Celgene Corporation (CELG): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Celgene Corporation ( CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Celgene Corporation rose $1.80 (1.6%) to $113.72 on average volume. Throughout the day, 3.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.8 million shares. The stock ranged in a price between $111.47-$113.88 after having opened the day at $112 as compared to the previous trading day's close of $111.92. Other companies within the Drugs industry that increased today were: Vermillion ( VRML), up 15%, Opexa Therapeutics ( OPXA), up 14.6%, Imprimis Pharmaceuticals ( IMMY), up 14.3%, and Codexis ( CDXS), up 10.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $46.63 billion and is part of the health care sector. The company has a P/E ratio of 33.7, above the S&P 500 P/E ratio of 17.7. Shares are up 42.6% year to date as of the close of trading on Monday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Delcath Systems ( DCTH), down 10.3%, XenoPort ( XNPT), down 10.1%, Novogen ( NVGN), down 9.1%, and Simcere Pharmaceutical Group ( SCR), down 8.5%, were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern